Case Study: Abveris achieves rapid discovery of Target X antibodies with Twist Bioscience's Beacon-based B cell screening

Abveris discovers 95 unique antibody sequences in 29 days with Twist Bioscience

Abveris required rapid antibody discovery against a challenging cell surface receptor target, which was suspected to be poorly immunogenic. They faced a tight timeline and the technical challenge of performing cell-based screening on adherent cell lines using Twist Bioscience's Beacon platform.

Twist Bioscience implemented an accelerated immunization protocol and a proprietary method to load over 10,000 plasma B cells for on-chip screening. This solution enabled Abveris to go from immunization to 95 unique antibody sequences in just 29 days. The majority of recombinantly expressed antibodies successfully retained their binding activity, delivering a diverse panel of validated binders to meet the partner's urgent timeline.

Abveris